The outcome was unknown at 11am CET on 4 November, with Republican President Donald Trump and his Democrat challenger Joe Biden neck and neck in the race for the White House. The Democrats were favorites to retain control of the US House of Representatives, but the contest for currently Republican controlled Senate was more finely balanced. Predictions for a ‘blue sweep’ – where the Democrats win everything – have not materialized.
“I really think it's difficult to say who is going to win, which means you should not take a position on this at all until we know for sure,” says Blokland, senior portfolio manager and Head of Robeco’s Multi-Asset team. “Currently it’s hard to say who will win, which makes life pretty easy because you don't have to do anything unless you had positioned yourself for one of these outcomes (we didn't).”
“We’re currently neutral in the portfolio. We have a 1% overweight in commodities, and if Trump does win, commodities like oil would probably rally. Tech stocks are likely to continue to outperform. We have seen some unwinding of the ‘blue sweep’ trades, which have all gone down, while everything that is value is cyclical. The euro/dollar has gone down, and there has been a sharp drop in the 10-year US Treasury bond yield, which is down 10 basis points now.”
Blokland says what really matters is whether there is a clear majority for either the Republicans or the Democrats in the White House and Congress. This will determine the level of fiscal stimulus to combat the coronavirus economic slowdown, and ultimately the earnings of companies in which his fund invests.
“Fiscal stimulus could be anywhere around USD 2 trillion with a clear majority for one side in the House of Representatives and Senate, and perhaps only half a trillion if you get stuck in one of these middle outcomes,” he says.
“If Biden wins, then two things will happen. If it's a blue sweep, then you will get a massive amount of fiscal stimulus, but you also get things like minimum wage hikes and tax rises. So, companies’ earnings per share are likely to go down a little bit on that.”
“In such a blue sweep, you should buy everything outside of the US, because there would be massive bond issuance, a lower dollar, and lower spreads from lower geopolitical tensions, since Trump is clearly going to go hard after China if he wins.”
“If it’s marginal, you still get the stimulus, but the Republicans will block any minimum wage legislation, and calculations suggest that earnings per share may actually go up in this scenario. If Biden wins but you also have a Republican Senate, then the least amount of fiscal stimulus would occur, and the calculation there is for a slightly negative impact on earnings per share.”
However, all this is not all that significant when considering that the biggest stimulus of all would come from finding a cure for the coronavirus, he says. “What the world really needs is a vaccine, and a return to some kind of normal, in which case we could see earnings per share rise by 20%,” Blokland says.
“The variation in EPS under different elections scenarios are much smaller in magnitudes, as stimulus and potential tax hikes cancel each other out.”
“So, for sure, we have all these combinations of potential outcomes, but the overall impact on earnings depends on the vaccine, not on the US elections.”
The final results of the elections may not be known until Friday 6 November, and could still be subject to legal challenge by one side or the other.
The information contained on these pages is for marketing purposes and solely intended for Qualified Investors in accordance with the Swiss Collective Investment Schemes Act of 23 June 2006 (“CISA”) domiciled in Switzerland, Professional Clients in accordance with Annex II of the Markets in Financial Instruments Directive II (“MiFID II”) domiciled in the European Union und European Economic Area with a license to distribute / promote financial instruments in such capacity or herewith requesting respective information on products and services in their capacity as Professional Clients.
The Funds are domiciled in Luxembourg and The Netherlands. ACOLIN Fund Services AG, postal address: Affolternstrasse 56, 8050 Zürich, acts as the Swiss representative of the Fund(s). UBS Switzerland AG, Bahnhofstrasse 45, 8001 Zurich, postal address: Europastrasse 2, P.O. Box, CH-8152 Opfikon, acts as the Swiss paying agent. The prospectus, the Key Investor Information Documents (KIIDs), the articles of association, the annual and semi-annual reports of the Fund(s) may be obtained, on simple request and free of charge, at the office of the Swiss representative ACOLIN Fund Services AG. The prospectuses are also available via the website www.robeco.ch. Some funds about which information is shown on these pages may fall outside the scope of the Swiss Collective Investment Schemes Act of 26 June 2006 (“CISA”) and therefore do not (need to) have a license from or registration with the Swiss Financial Market Supervisory Authority (FINMA).
Some funds about which information is shown on this website may not be available in your domicile country. Please check the registration status in your respective domicile country. To view the RobecoSwitzerland Ltd. products that are registered/available in your country, please go to the respective Fund Selector, which can be found on this website and select your country of domicile.
Neither information nor any opinion expressed on this website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. An investment in a Robeco Switzerland Ltd. product should only be made after reading the related legal documents such as management regulations, prospectuses, annual and semi-annual reports.